IDH1 and central nervous system cancer: Both models in Table 2 are for all glioma patients, whereas the two postoperative models in Table 3 are for glioblastoma, IDH-wildtype (GBM) patients and diffuse astrocytoma, IDH-mutant (DA) patients, respectively.